Zevra Therapeutics (ZVRA) Stock Forecast, Price Target & Predictions

OverviewRevenue Financials Chart Transcripts

ZVRA Stock Forecast

Zevra Therapeutics stock forecast is as follows: an average price target of $21.00 (represents a 147.35% upside from ZVRA’s last price of $8.49) and a rating consensus of 'Buy', based on 9 wall street analysts offering a 1-year stock forecast.

ZVRA Price Target

The average price target for Zevra Therapeutics (ZVRA) is $21.00 based on 1-year price targets from 9 Wall Street analysts in the past 3 months, with a price target range of $25.00 to $17.00. This represents a potential 147.35% upside from ZVRA's last price of $8.49.

ZVRA Analyst Ratings

Buy

According to 9 Wall Street analysts, Zevra Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for ZVRA stock is 0 'Strong Buy' (0.00%), 8 'Buy' (88.89%), 1 'Hold' (11.11%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Zevra Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Sep 24, 2024	Jonathan Aschoff	Roth Capital	$21.00	$7.58	177.04%	147.35%
Sep 24, 2024	Jason McCarthy	Maxim Group	$25.00	$7.58	229.82%	194.46%
Sep 24, 2024	Jason Butler	JMP Securities	$17.00	$7.58	124.27%	100.24%
Sep 23, 2024	Oren Livnat	H.C. Wainwright	$20.00	$7.92	152.52%	135.57%
Sep 18, 2024	Sumant Kulkarni	Canaccord Genuity	$22.00	$7.53	192.16%	159.13%

The latest Zevra Therapeutics stock forecast, released on Sep 24, 2024 by Jonathan Aschoff from Roth Capital, set a price target of $21.00, which represents a 177.04% increase from the stock price at the time of the forecast ($7.58), and a 147.35% increase from ZVRA last price ($8.49).

Zevra Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	-	5	5
Avg Price Target	-	$21.00	$21.00
Last Closing Price	$8.49	$8.49	$8.49
Upside/Downside	-100.00%	147.35%	147.35%

In the current month, the average price target of Zevra Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Zevra Therapeutics's last price of $8.49. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 07, 2024	Guggenheim		Buy	Initialise
Sep 24, 2024	Maxim Group	Market Outperform	Market Outperform	Hold
Sep 24, 2024	JMP Securities	Underperform	Underperform	Hold
Sep 24, 2024	Maxim Group	Buy	Buy	Hold
Sep 24, 2024	JMP Securities	Market Outperform	Outperform	Initialise
Sep 24, 2024	JMP Securities		Market Outperform	Initialise
Sep 20, 2024	H.C. Wainwright	Buy	Buy	Hold
Sep 18, 2024	Canaccord Genuity	Buy	Buy	Hold
Aug 05, 2024	H.C. Wainwright	Buy	Buy	Hold
Jun 10, 2024	Cantor Fitzgerald	Overweight	Overweight	Hold
Dec 28, 2023	Canaccord Genuity	Buy	Buy	Hold
Mar 17, 2023	BTIG		Buy	Initialise
Mar 17, 2023	Maxim Group		Buy	Initialise
Mar 17, 2023	WestPark Capital		Buy	Initialise
Mar 17, 2023	SVB Leerink		Market Perform	Initialise
Mar 17, 2023	Citigroup		Buy	Initialise

Zevra Therapeutics's last stock rating was published by Guggenheim on Oct 07, 2024. The company Initialise its ZVRA rating from "null" to "Buy".

Zevra Therapeutics Financial Forecast

Zevra Therapeutics Revenue Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$13.22M	-	-	$2.88M	$2.32M	$2.87M	$1.30M	$3.96M	-	-	-	-	-	-
Avg Forecast	$70.84M	$68.31M	$63.26M	$60.73M	$47.86M	$46.12M	$43.54M	$40.09M	$26.83M	$22.35M	$18.65M	$27.07M	$8.78M	$4.87M	$4.37M	$3.76M	$11.73M	$3.38M	$3.07M	$2.66M	$3.11M	$3.01M	$1.75M	$3.06M	$2.23M	$2.15M	$12.10M	$2.10M	$1.96M	$1.90M
High Forecast	$163.47M	$157.64M	$145.97M	$140.14M	$110.44M	$106.43M	$100.48M	$92.50M	$61.90M	$51.57M	$43.04M	$32.67M	$9.03M	$11.24M	$10.07M	$3.76M	$11.99M	$3.38M	$7.08M	$6.13M	$7.17M	$3.01M	$1.75M	$3.06M	$2.23M	$2.15M	$12.10M	$2.10M	$1.96M	$1.90M
Low Forecast	$37.46M	$36.12M	$33.45M	$32.12M	$25.31M	$24.39M	$23.03M	$21.20M	$14.19M	$11.82M	$9.86M	$21.46M	$8.33M	$2.57M	$2.31M	$3.76M	$11.60M	$3.38M	$1.62M	$1.40M	$1.64M	$3.01M	$1.75M	$3.06M	$2.23M	$2.15M	$12.10M	$2.10M	$1.96M	$1.90M
# Analysts	1	1	1	1	1	1	1	1	1	1	1	3	5	4	2	2	4	2	2	2	1	1	1	1	2	2	2	2	2	2
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.13%	-	-	1.08%	0.75%	0.95%	0.74%	1.29%	-	-	-	-	-	-

Zevra Therapeutics's average Quarter revenue forecast for Mar 24 based on 2 analysts is $3.76M, with a low forecast of $3.76M, and a high forecast of $3.76M. ZVRA's average Quarter revenue forecast represents a -71.56% decrease compared to the company's last Quarter revenue of $13.22M (Dec 23).

Zevra Therapeutics EBITDA Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	1	1	1	1	1	1	1	1	1	1	1	3	5	4	2	2	4	2	2	2	1	1	1	1	2	2	2	2	2	2
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-14.67M	-	-	$-11.88M	$9.47M	$-6.15M	$-7.09M	$-1.79M	-	-	-	-	-	-
Avg Forecast	$-52.20M	$-50.33M	$-46.61M	$-44.75M	$-35.26M	$-33.98M	$-32.08M	$-29.54M	$-19.77M	$-16.47M	$-13.74M	$-19.94M	$-6.47M	$-3.59M	$-3.22M	$-2.77M	$-8.64M	$-2.49M	$-2.26M	$-1.96M	$-2.29M	$-1.85M	$-1.07M	$-1.88M	$-1.37M	$-1.32M	$-7.44M	$-1.29M	$-1.21M	$-1.17M
High Forecast	$-27.60M	$-26.62M	$-24.65M	$-23.66M	$-18.65M	$-17.97M	$-16.97M	$-15.62M	$-10.45M	$-8.71M	$-7.27M	$-15.81M	$-6.14M	$-1.90M	$-1.70M	$-2.77M	$-8.55M	$-2.49M	$-1.19M	$-1.03M	$-1.21M	$-1.85M	$-1.07M	$-1.88M	$-1.37M	$-1.32M	$-7.44M	$-1.29M	$-1.21M	$-1.17M
Low Forecast	$-120.44M	$-116.15M	$-107.55M	$-103.26M	$-81.37M	$-78.42M	$-74.03M	$-68.15M	$-45.61M	$-38.00M	$-31.71M	$-24.07M	$-6.65M	$-8.28M	$-7.42M	$-2.77M	$-8.83M	$-2.49M	$-5.21M	$-4.51M	$-5.28M	$-1.85M	$-1.07M	$-1.88M	$-1.37M	$-1.32M	$-7.44M	$-1.29M	$-1.21M	$-1.17M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.70%	-	-	6.07%	-4.14%	3.32%	6.60%	0.95%	-	-	-	-	-	-

2 analysts predict ZVRA's average Quarter EBITDA for Mar 23 to be $-1.96M, with a high of $-1.03M and a low of $-4.51M. This is -120.66% lower than Zevra Therapeutics's previous annual EBITDA (Dec 22) of $9.47M.

Zevra Therapeutics Net Income Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	1	1	1	1	1	1	1	1	1	1	1	3	5	4	2	2	4	2	2	2	1	1	1	1	2	2	2	2	2	2
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-15.15M	-	-	$-11.77M	$-9.02M	$-6.62M	$-24.04M	$-1.86M	-	-	-	-	-	-
Avg Forecast	-	-	-	-	$9.10M	$6.75M	$7.43M	$2.75M	$-3.43M	$-6.61M	$-9.32M	$-1.35M	$-19.06M	$-19.67M	$-21.71M	$-22.31M	$-12.83M	$-14.22M	$-14.82M	$-11.12M	$-8.84M	$-6.56M	$-5.87M	$-2.30M	$-3.14M	$-3.35M	$9.43M	$-7.12M	$-28.07M	$-33.52M
High Forecast	-	-	-	-	$24.58M	$18.21M	$20.06M	$7.42M	$-1.33M	$-2.56M	$-3.61M	$-524.83K	$-17.60M	$-7.62M	$-8.41M	$-8.64M	$-8.98M	$-5.51M	$-5.74M	$-4.31M	$-3.43M	$-6.56M	$-5.87M	$-2.30M	$-3.14M	$-3.35M	$9.43M	$-7.12M	$-28.07M	$-33.52M
Low Forecast	-	-	-	-	$3.53M	$2.61M	$2.88M	$1.07M	$-9.25M	$-17.85M	$-25.17M	$-3.66M	$-20.53M	$-53.11M	$-58.60M	$-60.23M	$-16.04M	$-38.40M	$-40.01M	$-30.01M	$-23.88M	$-6.56M	$-5.87M	$-2.30M	$-3.14M	$-3.35M	$9.43M	$-7.12M	$-28.07M	$-33.52M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.18%	-	-	1.06%	1.02%	1.01%	4.10%	0.81%	-	-	-	-	-	-

Zevra Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ZVRA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Zevra Therapeutics SG&A Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	1	1	1	1	1	1	1	1	1	1	1	3	5	4	2	2	4	2	2	2	1	1	1	1	2	2	2	2	2	2
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$14.66M	-	-	$6.83M	$5.08M	$3.97M	$3.56M	$2.73M	-	-	-	-	-	-
Avg Forecast	$63.57M	$61.31M	$56.77M	$54.50M	$42.95M	$41.39M	$39.08M	$35.97M	$24.07M	$20.06M	$16.74M	$24.29M	$7.87M	$4.37M	$3.92M	$3.37M	$10.53M	$3.03M	$2.75M	$2.38M	$2.79M	$2.70M	$1.57M	$2.75M	$2.01M	$1.93M	$10.86M	$1.88M	$1.76M	$1.71M
High Forecast	$146.70M	$141.47M	$131.00M	$125.76M	$99.11M	$95.51M	$90.17M	$83.01M	$55.55M	$46.28M	$38.62M	$29.32M	$8.10M	$10.08M	$9.04M	$3.37M	$10.76M	$3.03M	$6.35M	$5.50M	$6.43M	$2.70M	$1.57M	$2.75M	$2.01M	$1.93M	$10.86M	$1.88M	$1.76M	$1.71M
Low Forecast	$33.62M	$32.42M	$30.02M	$28.82M	$22.71M	$21.89M	$20.66M	$19.02M	$12.73M	$10.61M	$8.85M	$19.26M	$7.47M	$2.31M	$2.07M	$3.37M	$10.41M	$3.03M	$1.46M	$1.26M	$1.47M	$2.70M	$1.57M	$2.75M	$2.01M	$1.93M	$10.86M	$1.88M	$1.76M	$1.71M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.39%	-	-	2.87%	1.82%	1.47%	2.27%	0.99%	-	-	-	-	-	-

Zevra Therapeutics's average Quarter SG&A projection for Mar 24 is $3.37M, based on 2 Wall Street analysts, with a range of $3.37M to $3.37M. The forecast indicates a -76.99% fall compared to ZVRA last annual SG&A of $14.66M (Dec 23).

Zevra Therapeutics EPS Forecast

	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20
# Analysts	1	1	1	1	1	1	1	1	1	1	1	3	5	4	2	2	4	2	2	2	1	1	1	1	2	2	2	2	2	2
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-0.40	-	-	$-0.34	$-0.26	$-0.19	$-0.70	$-0.05	-	-	-	-	-	-
Avg Forecast	-	-	-	-	$0.19	$0.14	$0.16	$0.06	$-0.07	$-0.14	$-0.20	$-0.03	$-0.40	$-0.41	$-0.45	$-0.47	$-0.27	$-0.30	$-0.31	$-0.23	$-0.18	$-0.16	$-0.14	$-0.06	$-0.07	$-0.08	$0.23	$-0.17	$-0.67	$-0.80
High Forecast	-	-	-	-	$0.51	$0.38	$0.42	$0.16	$-0.03	$-0.05	$-0.08	$-0.01	$-0.37	$-0.16	$-0.18	$-0.18	$-0.19	$-0.12	$-0.12	$-0.09	$-0.07	$-0.16	$-0.14	$-0.06	$-0.07	$-0.08	$0.23	$-0.17	$-0.67	$-0.80
Low Forecast	-	-	-	-	$0.07	$0.05	$0.06	$0.02	$-0.19	$-0.37	$-0.53	$-0.08	$-0.43	$-1.11	$-1.23	$-1.26	$-0.34	$-0.80	$-0.84	$-0.63	$-0.50	$-0.16	$-0.14	$-0.06	$-0.07	$-0.08	$0.23	$-0.17	$-0.67	$-0.80
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.49%	-	-	1.46%	1.41%	1.21%	5.00%	0.98%	-	-	-	-	-	-

According to undefined Wall Street analysts, Zevra Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ZVRA previous annual EPS of $NaN (undefined).

Zevra Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
STTK	Shattuck Labs	$1.15	$12.00	943.48%	Hold
PASG	Passage Bio	$0.67	$6.00	795.52%	Buy
RVPH	Reviva Pharmaceuticals	$1.40	$10.00	614.29%	Buy
FDMT	4D Molecular Therapeutics	$6.32	$38.33	506.49%	Buy
MOLN	Molecular Partners	$5.25	$29.00	452.38%	Buy
CCCC	C4 Therapeutics	$4.05	$20.00	393.83%	Buy
PMVP	PMV Pharmaceuticals	$1.52	$6.00	294.74%	Buy
ANTX	AN2 Therapeutics	$1.34	$5.00	273.13%	Buy
AKBA	Akebia Therapeutics	$1.87	$6.50	247.59%	Buy
FHTX	Foghorn Therapeutics	$5.51	$14.00	154.08%	Buy
ZVRA	Zevra Therapeutics	$8.48	$21.00	147.64%	Buy
PHVS	Pharvaris	$18.49	$42.00	127.15%	Buy
STOK	Stoke Therapeutics	$12.10	$26.50	119.01%	Buy
TYRA	Tyra Biosciences	$15.22	$31.75	108.61%	Buy

ZVRA Forecast FAQ

Is Zevra Therapeutics a good buy?

Yes, according to 9 Wall Street analysts, Zevra Therapeutics (ZVRA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 8 'Buy' recommendations, accounting for 88.89% of ZVRA's total ratings.

What is ZVRA's price target?

Zevra Therapeutics (ZVRA) average price target is $21 with a range of $17 to $25, implying a 147.35% from its last price of $8.49. The data is based on 9 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Zevra Therapeutics stock go up soon?

According to Wall Street analysts' prediction for ZVRA stock, the company can go up by 147.35% (from the last price of $8.49 to the average price target of $21), up by 194.46% based on the highest stock price target, and up by 100.24% based on the lowest stock price target.

Can Zevra Therapeutics stock reach $13?

ZVRA's average twelve months analyst stock price target of $21 supports the claim that Zevra Therapeutics can reach $13 in the near future.

What are Zevra Therapeutics's analysts' financial forecasts?

Zevra Therapeutics's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $177.61M (high $409.85M, low $93.92M), average EBITDA is $-131M (high $-69.203M, low $-302M), average net income is $26.03M (high $70.27M, low $10.08M), average SG&A $159.39M (high $367.8M, low $84.29M), and average EPS is $0.544 (high $1.47, low $0.211). ZVRA's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $263.14M (high $607.21M, low $139.15M), average EBITDA is $-194M (high $-103M, low $-447M), average net income is $0 (high $0, low $0), average SG&A $236.15M (high $544.93M, low $124.88M), and average EPS is $0 (high $0, low $0).

Did the ZVRA's actual financial results beat the analysts' financial forecasts?

Based on Zevra Therapeutics's last annual report (Dec 2023), the company's revenue was $27.46M, beating the average analysts forecast of $20.83M by 31.81%. Apple's EBITDA was $-49.604M, beating the average prediction of $-15.35M by 223.15%. The company's net income was $-46.049M, missing the average estimation of $-52.988M by -13.10%. Apple's SG&A was $34.31M, beating the average forecast of $18.7M by 83.53%. Lastly, the company's EPS was $-1.3, beating the average prediction of $-1.108 by 17.29%. In terms of the last quarterly report (Dec 2023), Zevra Therapeutics's revenue was $13.22M, beating the average analysts' forecast of $11.73M by 12.66%. The company's EBITDA was $-14.671M, beating the average prediction of $-8.644M by 69.72%. Zevra Therapeutics's net income was $-15.153M, beating the average estimation of $-12.829M by 18.12%. The company's SG&A was $14.66M, beating the average forecast of $10.53M by 39.21%. Lastly, the company's EPS was $-0.4, beating the average prediction of $-0.268 by 49.07%